0GQU Stock Chart & Stats
kr0.04
kr0.01(10.43%)
At close: 4:00 PM EST
kr0.04
kr0.01(10.43%)
Day’s Range― - ―
52-Week Rangekr3.81 - kr13.92
Previous CloseN/A
Volume200.00K
Average Volume (3M)196.00
Market Cap
kr118.75M
Enterprise Valuekr106.98
Total Cash (Recent Filing)kr43.90M
Total Debt (Recent Filing)kr100.00K
Price to Earnings (P/E)―
Beta1.91
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding26,360,670
10 Day Avg. Volume0
30 Day Avg. Volume196
Financial Highlights & Ratios
PEG Ratio2.36
Price to Book (P/B)111.47
Price to Sales (P/S)0.00
P/FCF Ratio-191.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr21.50M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageThe sharp reduction in debt and near-zero debt-to-equity position provide financial flexibility for a clinical-stage company. Lower leverage limits interest and refinancing pressure, allowing more capital to remain available for advancing therapeutic candidates and managing future funding needs.
Narrowing LossesLosses have narrowed materially over several reporting periods, indicating improving cost discipline or reduced operating drag even though profitability remains negative. If sustained, this trajectory could extend the company’s available resources and reduce the pace at which capital is consumed.
Improving Cash BurnOperating cash outflows have improved substantially from earlier periods, showing that cash consumption is becoming less severe. This is supportive of financial durability over the next several quarters, although the company still needs to convert its development activities into revenue or other funding sources.
Bears Say
No Reported RevenueZero reported revenue means the business has not yet demonstrated a recurring commercial sales base, leaving financial performance tied to development progress and potential pipeline monetization. Without revenue, operating costs cannot be funded internally through customers, limiting scalability and earnings visibility.
Persistent Cash ConsumptionContinued negative operating and free cash flow shows that the company is consuming cash rather than generating it from operations. This can constrain investment in clinical programs and increase reliance on future financing, partnerships, or other pipeline monetization to sustain development.
Declining Equity And Negative ReturnsThe decline in equity alongside persistently negative returns indicates that ongoing losses are eroding the financial base. Continued deterioration could reduce funding flexibility and increase value-dilution risk if additional capital is required before the pipeline produces meaningful commercial or partnering proceeds.
Active Biotech AB News
0GQU FAQ
What was Active Biotech AB’s price range in the past 12 months?
Active Biotech AB lowest share price was kr3.81 and its highest was kr13.92 in the past 12 months.
What is Active Biotech AB’s market cap?
Active Biotech AB’s market cap is kr118.75M.
When is Active Biotech AB’s upcoming earnings report date?
Active Biotech AB’s upcoming earnings report date is Nov 05, 2026 which is in 54 days.
How were Active Biotech AB’s earnings last quarter?
Active Biotech AB released its earnings results on Aug 20, 2026. The company reported -kr0.383 earnings per share for the quarter.
Is Active Biotech AB overvalued?
According to Wall Street analysts Active Biotech AB’s price is currently Overvalued.
Does Active Biotech AB pay dividends?
Active Biotech AB does not currently pay dividends.
What is Active Biotech AB’s EPS estimate?
Active Biotech AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Active Biotech AB have?
Active Biotech AB has 26,360,670 shares outstanding.
What happened to Active Biotech AB’s price movement after its last earnings report?
Active Biotech AB reported an EPS of -kr0.383 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Active Biotech AB?
Currently, no hedge funds are holding shares in GB:0GQU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Active Biotech AB
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors. The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas and Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
Oncopeptides AB
―
SynAct Pharma AB
―
Cantargia AB
―